哌拉西林-他唑巴坦联合替考拉宁与联合万古霉素的急性肾损伤风险比较:系统评价与荟萃分析
该系统评价与荟萃分析纳入5项队列研究共908例住院患者,比较哌拉西林-他唑巴坦联合替考拉宁(TZP-TEI)与联合万古霉素(TZP-VAN)的肾安全性。结果显示TZP-TEI组急性肾损伤(AKI)发生率显著低于TZP-VAN组(OR 0.52;95%CI 0.30-0.89;p=0.02;I2=51%),而AKI恢复和30天全因死亡率无显著差异。
要点
- TZP-TEI较TZP-VAN显著降低AKI发生率(OR 0.52;95%CI 0.30-0.89)。
- 两组AKI恢复(OR 0.68;95%CI 0.41-1.12)和30天全因死亡率(OR 1.34;95%CI 0.77-2.32)无显著差异。
- 亚组分析显示不同AKI严重程度分期方向一致,但需进一步研究验证。
核心结论
- TZP-TEI组合的AKI发生率显著低于TZP-VAN组合。
- 两组在AKI恢复和30天全因死亡率方面无统计学显著差异。
研究设计与样本
- 系统评价与荟萃分析,检索PubMed、Scopus和Cochrane Central数据库。
- 纳入5项比较TZP-TEI与TZP-VAN的队列研究,共908例住院患者,其中4项采用倾向评分匹配(PSM)。
- 纳入研究报告年龄范围为56.8至79岁。
主要发现
- TZP-TEI组AKI发生率显著低于TZP-VAN组(OR 0.52;95%CI 0.30-0.89;p=0.02;I2=51%)。
- AKI恢复率两组无显著差异(OR 0.68;95%CI 0.41-1.12;p=0.13;I2=0%)。
- 30天全因死亡率两组无显著差异(OR 1.34;95%CI 0.77-2.32;p=0.30;I2=0%)。
- 按AKI严重程度(KDIGO 1-3期或RIFLE标准)分层亚组分析方向一致,PSM和非PSM队列内均无显著差异。
关键数值与推荐
- 主要结局AKI采用KDIGO或RIFLE标准定义。
- TZP-TEI较TZP-VAN的AKI风险OR为0.52(95%CI 0.30-0.89;p=0.02;I2=51%)。
- AKI恢复OR为0.68(95%CI 0.41-1.12;p=0.13;I2=0%)。
- 30天全因死亡率OR为1.34(95%CI 0.77-2.32;p=0.30;I2=0%)。
临床怎么用
- 对于需要哌拉西林-他唑巴坦联合抗MRSA覆盖的住院患者,可考虑替考拉宁替代万古霉素以降低AKI风险。
- 替考拉宁在TZP-TEI组合中的剂量优化及治疗药物监测(TDM)在高危住院患者中的应用有待进一步研究明确。
局限性
- 纳入研究数量较少(5项队列研究),总样本量908例。
- 部分研究未采用倾向评分匹配,可能存在混杂偏倚。
- 替考拉宁在联合方案中的最佳剂量及TDM实施尚未明确,需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Piperacillin-tazobactam combined with vancomycin is widely employed for broad-spectrum empiric coverage but has been increasingly associated with acute kidney injury (AKI). The comparative renal safety of substituting vancomycin with teicoplanin remains uncertain. OBJECTIVE: This meta-analysis aimed to evaluate renal outcomes between piperacillin-tazobactam plus teicoplanin (TZP-TEI) versus piperacillin-tazobactam plus vancomycin (TZP-VAN). METHODS: PubMed, Scopus, and Cochrane Central were searched for studies comparing TZP-TEI versus TZP-VAN in hospitalized patients. The primary outcome was AKI incidence, defined by Kidney disease: Improving global outcomes (KDIGO) or RIFLE (Risk of renal dysfunction, Injury to kidney, Failure or Loss of kidney function, and End-stage kidney disease) criteria. Data were analyzed using Review Manager, with heterogeneity assessed via the I2 statistic. RESULTS: A total of 908 patients were included from five cohort studies, four of which applied propensity-score matching (PSM), with reported ages ranging from 56.8 to 79 years. The TZP-TEI regimen was associated with a significantly reduced rate of AKI compared with TZP-VAN (odds ratio [OR] 0.52; 95% confidence interval [CI] 0.30-0.89; p = 0.02; I2 = 51%). No statistically significant differences were observed between groups for AKI recovery (OR 0.68; 95% CI 0.41-1.12; p = 0.13; I2 = 0%) or for 30-day all-cause mortality (OR 1.34; 95% CI 0.77-2.32; p = 0.30; I2 = 0%). Subgroup analyses stratified by AKI severity (KDIGO stages 1-3 or RIFLE criteria) demonstrated consistent directionality across stages, with no significant differences observed within PSM or non-PSM cohorts. CONCLUSION: The TZP-TEI combination was associated with a significantly lower incidence of AKI than was TZP-VAN. Further studies are warranted to validate these findings, optimize teicoplanin dosing within the TZP-TEI combination, and inform therapeutic drug monitoring implementation in high-risk hospitalized patients.
引用
- Mohammad S, Ghazal H, Rahimeh W, et al. Comparative Risk of Acute Kidney Injury with Piperacillin-Tazobactam Plus Teicoplanin Versus Piperacillin-Tazobactam Plus Vancomycin: A Systematic Review and Meta-Analysis. Drug Saf. 2025. PMID: 40940625. doi:10.1007/s40264-025-01611-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。